{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:52Z","timestamp":1772165692346,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>C3-glomerulonephritis can lead to progressive renal impairment from complement-mediated glomerular injury. Incidence and outcomes of C3-glomerulonephritis are not known in the New Zealand population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed all cases of C3-glomerulonephritis from the past 10\u2009years at a tertiary referral centre in New Zealand. Descriptive information on baseline characteristics and clinical outcomes was collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six patients were included (16 men; mean\u2009\u00b1\u2009SD age 44\u2009\u00b1\u200925\u2009years) with a median follow-up of 30\u2009months. Disease incidence was 1.3 cases per million individuals, of which 42% were Pacific Islanders. Most patients presented with renal impairment, with a median (IQR) creatinine at diagnosis of 210 (146\u2013300) \u03bcmol\/L, and 11 (42%) patients presented with nephrotic syndrome. Seven (27%) patients progressed to end stage renal disease and 2 (8%) had died. End stage renal disease occurred in 20% of patients treated with immunosuppression and in 50% of those not treated. Complete remission was seen in 25% of patients treated with some form of immunosuppression and in 17% of those not treated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results are consistent with previous descriptions of C3-glomerulonephritis. There was a suggestion of better clinical outcomes in patients treated with immunosuppression. There was a higher disease incidence in Pacific Islanders, which may indicate an underlying susceptibility to complement dysfunction in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-02056-5","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T10:15:20Z","timestamp":1600337720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["C3-glomerulonephritis in New Zealand \u2013 a case series"],"prefix":"10.1186","volume":"21","author":[{"given":"Luke J.","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-7482","authenticated-orcid":false,"given":"Hari","family":"Talreja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"issue":"9","key":"2056_CR1","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2007030356","volume":"18","author":"RJH Smith","year":"2007","unstructured":"Smith RJH, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18(9):2447\u201356.","journal-title":"J Am Soc Nephrol"},{"key":"2056_CR2","doi-asserted-by":"publisher","unstructured":"Pan X, Xu J, Ren H, Zhang W, Xu Y, Shen P, et al. Changing spectrum of biopsy-proven primary glomerular diseases over the Past 15 Years: a single-center study in china. Contrib Nephrol. 2013:22\u201330. Available from:. https:\/\/doi.org\/10.1159\/000348638.","DOI":"10.1159\/000348638"},{"key":"2056_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000348478","volume":"181","author":"Y Lu","year":"2013","unstructured":"Lu Y, Shen P, Li X, Xu Y, Pan X, Wang W, et al. Re-evaluation of the classification system for membranoproliferative glomerulonephritis. Contrib Nephrol. 2013;181:175\u201384.","journal-title":"Contrib Nephrol"},{"issue":"11","key":"2056_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneph.2012.213","volume":"8","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8(11):634.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2056_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.07110810","volume":"6","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC, Zhang Y, Nasr SH, Leung N, Vrana J, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol. 2011;6(5):1009\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2056_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","volume":"12","author":"R Schwertz","year":"2001","unstructured":"Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long-term follow-up. Pediatr Allergy Immunol. 2001;12:166\u201372. Available from:. https:\/\/doi.org\/10.1034\/j.1399-3038.2001.012003166.x.","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"2056_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","volume":"85","author":"J Hou","year":"2014","unstructured":"Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014;85(2):450\u20136.","journal-title":"Kidney Int"},{"issue":"6","key":"2056_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D\u2019Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079\u201389.","journal-title":"Kidney Int"},{"issue":"4","key":"2056_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, No\u00ebl L-H, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey M-A, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454\u201364.","journal-title":"Kidney Int"},{"issue":"4","key":"2056_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/path.1711410404","volume":"141","author":"CP Swainson","year":"1983","unstructured":"Swainson CP, Robson JS, Thomson D, MacDonald MK. Mesangiocapillary glomerulonephritis: a long-term study of 40 cases. J Pathol. 1983;141(4):449\u201368.","journal-title":"J Pathol"},{"issue":"1","key":"2056_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/cjn.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46\u201353. Available from. https:\/\/doi.org\/10.2215\/cjn.04700513.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2056_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","volume":"88","author":"C Rabasco","year":"2015","unstructured":"Rabasco C, Cavero T, Rom\u00e1n E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015;88(5):1153\u201360.","journal-title":"Kidney Int"},{"key":"2056_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheumatic Dis. 2012;71:1771\u201382. Available from. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201940.","journal-title":"Ann Rheumatic Dis"},{"key":"2056_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1651-2227.1996.tb14022.x","volume":"85","author":"R Schwertz","year":"1996","unstructured":"Schwertz R, Jong R, Gretz N, Kirschfink M, Anders D, Sch\u00e4rer K, et al. Outcome of idiopathic membranoproliferative glomerulonephritis in children. Acta Paediatrica. 1996;85:308\u201312. Available from. https:\/\/doi.org\/10.1111\/j.1651-2227.1996.tb14022.x.","journal-title":"Acta Paediatrica"},{"issue":"5","key":"2056_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7(5):748\u201356.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2056_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MNH.0b013e32835da24c","volume":"22","author":"CM Nester","year":"2013","unstructured":"Nester CM, Smith RJ. Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens. 2013;22(2):231\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"2056_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ajt.13042","volume":"15","author":"S Barbour","year":"2015","unstructured":"Barbour S, Gill JS. Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. Am J Transplant. 2015;15(2):312\u20139.","journal-title":"Am J Transplant"},{"issue":"3","key":"2056_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","volume":"62","author":"L Zand","year":"2013","unstructured":"Zand L, Kattah A, Fervenza FC, Smith RJH, Nasr SH, Zhang Y, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013;62(3):506\u201314.","journal-title":"Am J Kidney Dis"},{"key":"2056_CR19","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1046\/j.1523-1755.63.s83.26.x","volume":"83","author":"SP McDonald","year":"2003","unstructured":"McDonald SP, Russ GR. Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney Int Suppl. 2003;83:S123\u20137.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"2056_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00467-008-1086-5","volume":"24","author":"W Wong","year":"2009","unstructured":"Wong W, Morris MC, Zwi J. Outcome of severe acute post-streptococcal glomerulonephritis in New Zealand children. Pediatr Nephrol. 2009;24(5):1021\u20136.","journal-title":"Pediatr Nephrol"},{"key":"2056_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","volume":"94","author":"A Ravindran","year":"2018","unstructured":"Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94:178\u201386 Kidney Int. 2018 Nov;94(5):1025.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-02056-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02056-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T19:21:27Z","timestamp":1631820087000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02056-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2056"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02056-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-34038\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-34038\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"29 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study approval was obtained from Counties Manukau Health Research Office and Health and Disability Ethics Committees (HDEC) prior to study commencement. Ethics Reference Number: 18\/STH\/210; Research Registration Number: 798.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"399"}}